AARTIDRUGS:NSE-Aarti Drugs Limited (INR)

COMMON STOCK | Drug Manufacturers—Specialty & Generic | NSE

Last Closing Price

INR 972.25

Change

0.00 (0.00)%

Market Cap

INR 22.72B

Volume

0.46M

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Aarti Drugs Limited, through its subsidiaries, engages in the pharmaceuticals business in India and internationally. It offers active pharmaceutical ingredients in various therapeutic categories, including anti-inflammatory, cardioprotectants, antidiarrhoeals, antifungals, antiarthritis/osteoporosis, antibiotics, antidiabetics, Alzheimer's treatment, sedatives, vitamins, and alcoholism treatment. The company also provides pharmaceutical intermediate products comprising tinidazole, celecoxib, ciprofloxacin, clopidogrel, diclofenac, ketoconazole, nimesulide, raloxifene, and zolpidem; and specialty chemical products, such as benzene sulphonamide, benzene sulphonic acid, benzene sulphonic acid methyl ester, benzene sulphonyl chloride, cipro Q acid, levofloxacin Q acid, methyl nicotinate, N-methyl methane sulphonamide, diphenyl sulphone, norofloxacin Q acid, ofloxacin Q acid, ortho para toluene sulphonamide, ortho/para toluene sulphonic acid methyl ester, para chloro benzene sulphonamide, para chloro benzene sulphonyl chloride, para toluene sulphonamide, para toluene sulphonic acid methyl ester, para toluene sulphonyl chloride, and sodium benezene sulfinate. In addition, its products under development comprise Acamprosate for alcoholism; Dabigatran for use as an anticoagulant; Sevelamer for antihyperphosphatemia; Colsevelam for anti-cholestrol treatment; Drondarone and Olmesartan for the treatment of cardiovascular diseases; Valasartan for use as cardiprotectant; and Sitagliptin for use as an antidiabetic. Further, the company's pipeline product includes Mesalamine/Mesalazine and Loxoprofen Sodium for use as anti-inflammatory products; and Duloxetine for use as an antidepressant. Additionally, it offers contract manufacturing services. Aarti Drugs Limited was founded in 1984 and is based in Mumbai, India.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-05-31 )

Largest Industry Peers for Drug Manufacturers—Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
SUNPHARMA:NSE Sun Pharmaceutical Industries ..

N/A

INR1,137.88B 27.54 14.34
DRREDDY:NSE Dr. Reddy's Laboratories Limit..

N/A

INR675.04B 33.12 19.57
DIVISLAB:NSE Divi's Laboratories Limited

N/A

INR634.50B 47.38 30.87
AUROPHARMA:NSE Aurobindo Pharma Limited

N/A

INR436.91B 16.30 10.01
LUPIN:NSE Lupin Limited

N/A

INR394.21B 49.28 17.85
CADILAHC:NSE Cadila Healthcare Limited

N/A

INR352.73B 27.78 15.61
ALKEM:NSE Alkem Laboratories Limited

N/A

INR270.56B 25.13 18.52
IPCALAB:NSE Ipca Laboratories Limited

N/A

INR188.95B 31.65 20.33
APLLTD:NSE Alembic Pharmaceuticals Limite..

N/A

INR164.14B 22.29 16.57
AJANTPHARM:NSE Ajanta Pharma Limited

N/A

INR132.87B 30.41 18.30

ETFs Containing AARTIDRUGS

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers—Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 64.26% 91% A- 99% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 64.26% 91% A- 99% A+
Trailing 12 Months  
Capital Gain 70.81% 93% A 98% A+
Dividend Return 0.18% 11% F 7% F
Total Return 70.99% 93% A 98% A+
Trailing 5 Years  
Capital Gain 46.67% 64% D 80% B-
Dividend Return 1.92% 39% F 19% F
Total Return 48.59% 64% D 79% C+
Average Annual (5 Year Horizon)  
Capital Gain 0.01% 43% F 38% F
Dividend Return 0.36% 43% F 33% F
Total Return 0.37% 41% F 38% F
Risk Return Profile  
Volatility (Standard Deviation) 14.95% 93% A 92% A-
Risk Adjusted Return 2.47% 41% F 36% F
Market Capitalization 22.72B 58% F 75% C
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers—Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 19.96 52% F 27% F
Price/Book Ratio 3.83 27% F 13% F
Price / Cash Flow Ratio 9.06 56% F 27% F
EV/EBITDA 10.52 50% F 30% F
Management Effectiveness  
Return on Equity 23.65% 86% B 82% B-
Return on Invested Capital -8.35% 11% F 9% F
Return on Assets 8.76% 86% B 78% C+
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.67 43% F 58% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (INR)

Quarterly Financials (INR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.